Loading...
CPRX logo
CPRX
Catalyst Pharmaceuticals

Updated NCCN Guidelines Will Expand Rare Disease Diagnosis

Published
10 Sep 24
Updated
30 Apr 25
AnalystConsensusTarget's Fair Value
US$34.29
39.3% undervalued intrinsic discount
10 Sep
US$20.82
Loading
1Y
4.6%
7D
-0.1%

Author's Valuation

US$34.2939.3% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates8

Shared on30 Apr 25
Fair value Decreased 6.83%

Read more

Shared on23 Apr 25
Fair value Increased 0.38%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25
Fair value Increased 6.93%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Increased 2.87%

Read more

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25
Fair value Increased 5.54%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on11 Mar 25
Fair value Decreased 3.87%

AnalystConsensusTarget has decreased revenue growth from 13.9% to 9.9%.

Read more